Lupin has reported its performance for the second quarter ending September 30, 2014. These unaudited results were taken on record by the Board of Directors at a recently held meeting in Mumbai. The net sales grew by 18.4 per cent to Rs 31,168 million during Q2 FY 2014-15, up from Rs 26,315 million in Q2 FY 2013-14. In H1, FY 2014-15, the company posted YoY growth of 26.7 per cent to Rs 64,008 million from Rs 50,521 million.
Earnings before interest, tax, depreciation and amortization grew by 27.2 per cent to Rs 9,428 million during Q2 FY 2014-15, up from Rs 7,410 million in Q2 FY 2013-14. In H1, FY 2014-15, the company reported YoY growth of 45.8 per cent to Rs 20,864 million from Rs 14,314 million.
Profit before tax grew by 23.2 per cent to Rs 8,320 million during Q2 FY 2014-15, up from Rs 6,755 million in Q2 FY 2013-14. In H1, FY 2014-15, YoY growth of 43.6 per cent to Rs 18,645 million was reported from Rs.12,981 million.
Net profits grew by 55.1 per cent to Rs 6,300 million during Q2 FY 2014-15, up from Rs 4,062 million in Q2 FY 2013-14. In H1, FY 2014-15, the company posted YoY growth of 55.5 per cent to Rs 12,548 million from Rs 8,072 million.
Nilesh Gupta, Managing Director, Lupin said, “We have had a great first half driven by strong growth in the US, India, Japan and our API business. Our research pipeline is evolving well and we expect significant developments in the dermatology and inhalation space in the quarters to come.”
EP News Bureau– Mumbai
